+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country

  • ID: 5232500
  • Report
  • December 2020
  • Region: Europe
  • 137 pages
  • GMD Research

FEATURED COMPANIES

  • Aenova Group
  • CMIC Co. Ltd
  • Hospira, Inc.
  • Lonza Group
  • Pfizer CentreSource
  • Recipharm AB
The European pharmaceutical CDMO market accounted for $37.17 billion in 2019 and will grow by 6.7% annually over 2020-2030 owing to the rising demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures.

Highlighted with 47 tables and 86 figures, this 137-page report “Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country” is based on comprehensive research of the entire Europe pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies of the period 2015-2019 and provides a forecast from 2020 till 2030 with 2019 as the base year.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country.

Based on Category, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Pharmaceutical Industry
  • Biopharmaceutical Industry
Based on Service Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Pharmaceutical Contract Manufacturing Organization (CMO)
  • Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
  • Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
  • Secondary Packaging
Pharmaceutical Contract Research Organization (CRO)
  • CRO for Pre-clinical Development
  • CRO for Phase I Trials
  • CRO for Phase II Trials
  • CRO for Phase III Trials
  • CRO for Phase IV Trials
  • Laboratory Services
  • Consulting Services
  • Data Management Services
Based on Therapeutic Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Infectious Diseases
  • Oncology
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Central Nervous System
  • Pulmonary Disorders
  • Gastrointestinal Disorders
  • Other Therapeutic Applications
Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Academic Institutes
Geographically, the following national/local markets are fully investigated:
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe (further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Europe pharmaceutical CDMO market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Company Profiles of CMO:
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
Company Profiles of CRO:
  • Charles River Laboratories
  • CMIC Co. Ltd
  • Covance Inc.
  • Hangzhou Tigermed Consulting Co Ltd
  • ICON Plc
  • IQVIA Holdings Inc.
  • LSK Europe Pharma Service Co Ltd
  • Novotech Pty Ltd
  • PAREXEL International Corporation
  • Pharmaceutical Product Development LLC (PPD)
  • PRA Health Sciences Inc.
  • Quanticate Ltd
  • Samsung Bioepis Co. Ltd
  • SGS SA (SGS Life Sciences)
  • Syneos Health Inc.
  • WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aenova Group
  • CMIC Co. Ltd
  • Hospira, Inc.
  • Lonza Group
  • Pfizer CentreSource
  • Recipharm AB
1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 Segmentation of Europe Market by Category
3.1 Market Overview by Category
3.2 Pharmaceutical Industry
3.3 Biopharmaceutical Industry

4 Segmentation of Europe Market by Service Type
4.1 Market Overview by Service Type
4.2 Pharmaceutical Contract Manufacturing Organization (CMO)
4.2.1 Active Pharmaceutical Ingredients (API)
4.2.2 Finished Dosage Formulations (FDF)
4.2.3 Secondary Packaging
4.3 Pharmaceutical Contract Research Organization (CRO)
4.3.1 CRO for Pre-clinical Development
4.3.2 CRO for Phase I Trials
4.3.3 CRO for Phase II Trials
4.3.4 CRO for Phase III Trials
4.3.5 CRO for Phase IV Trials
4.3.6 Laboratory Services
4.3.7 Consulting Services
4.3.8 Data Management Services

5 Segmentation of Europe Market by Therapeutic Application
5.1 Market Overview by Therapeutic Application
5.2 Infectious Diseases
5.3 Oncology
5.4 Metabolic Disorders
5.5 Cardiovascular Disorders
5.6 Central Nervous System
5.7 Pulmonary Disorders
5.8 Gastrointestinal Disorders
5.9 Other Therapeutic Applications

6 Segmentation of Europe Market by End User
6.1 Market Overview by End User
6.2 Pharmaceutical & Biopharmaceutical Companies
6.3 Medical Device Companies
6.4 Academic Institutes

7 European Market 2019-2030 by Country
7.1 Overview of European Market
7.2 Germany
7.3 UK
7.4 France
7.5 Spain
7.6 Italy
7.7 Russia
7.8 Rest of European Market

8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
8.3.1 Company Profiles of CMO
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
8.3.2 Company Profiles of CRO
  • Charles River Laboratories
  • CMIC Co. Ltd
  • Covance Inc.
  • Hangzhou Tigermed Consulting Co Ltd
  • ICON Plc
  • IQVIA Holdings Inc.
  • LSK Europe Pharma Service Co Ltd
  • Novotech Pty Ltd
  • PAREXEL International Corporation
  • Pharmaceutical Product Development LLC (PPD)
  • PRA Health Sciences Inc.
  • Quanticate Ltd
  • Samsung Bioepis Co. Ltd
  • SGS SA (SGS Life Sciences)
  • Syneos Health Inc.
  • WuXi AppTec Inc.
9 Investing in Europe Market: Risk Assessment and Management
9.1 Risk Evaluation of Europe Market
9.2 Critical Success Factors (CSFs)

List of Tables
Table 1. Snapshot of Europe Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030
Table 2. Growth Rate of World Real GDP, 2017-2021
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn
Table 4. Worldwide Total Number of Registered Clinical Trials
Table 5. Main Product Trends and Market Opportunities in Europe Pharmaceutical CDMO Market
Table 6. Europe Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 7. Europe Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 8. Europe Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn
Table 9. Europe Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn
Table 10. Europe Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn
Table 11. Europe Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn
Table 12. Europe Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 13. Europe Pharmaceutical CDMO Market by End User, 2019-2030, $ bn
Table 14. Europe Pharmaceutical CDMO Market by Country, 2019-2030, $ bn
Table 15. Germany Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 16. Germany Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 17. Germany Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 18. UK Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 19. UK Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 20. UK Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 21. France Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 22. France Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 23. France Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 24. Spain Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 25. Spain Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 26. Spain Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 27. Italy Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 28. Italy Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 29. Italy Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 30. Russia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 31. Russia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 32. Russia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 33. Pharmaceutical CDMO Market in Rest of Europe by Country, 2019-2030, $ bn
Table 34. Breakdown of World CMO Market by Key Vendor, 2019, %
Table 35. Breakdown of World CRO Market by Key Vendor, 2019, %
Table 36. Aenova Group: Company Snapshot
Table 37. Aenova Group: Business Segmentation
Table 38. Aenova Group: Product Portfolio
Table 39. Aenova Group: Revenue, 2016-2018, $ bn
Table 40. Aenova Group: Recent Developments
Table 41. Charles River Laboratories: Company Snapshot
Table 42. Charles River Laboratories: Business Segmentation
Table 43. Charles River Laboratories: Product Portfolio
Table 44. Charles River Laboratories: Revenue, 2016-2018, $ bn
Table 45. Charles River Laboratories: Recent Developments
Table 46. Risk Evaluation for Investing in Europe Market, 2019-2030
Table 47. Critical Success Factors and Key Takeaways

List of Figures
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Europe Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Europe Pharmaceutical CDMO Market
Figure 8. Primary Restraints and Impact Factors of Europe Pharmaceutical CDMO Market
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Fiver Forces Analysis of Europe Pharmaceutical CDMO Market
Figure 11. Breakdown of Europe Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue
Figure 12. Europe Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)
Figure 13. Europe Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn
Figure 14. Europe Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn
Figure 15. Breakdown of Europe Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue
Figure 16. Europe Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%)
Figure 17. Europe Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn
Figure 18. Europe Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn
Figure 19. Europe Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn
Figure 20. Europe Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn
Figure 21. Europe Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn
Figure 22. Europe Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn
Figure 23. Europe Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn
Figure 24. Europe Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn
Figure 25. Europe Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn
Figure 26. Europe Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn
Figure 27. Europe Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn
Figure 28. Europe Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn
Figure 29. Europe Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn
Figure 30. Breakdown of Europe Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue
Figure 31. Europe Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)
Figure 32. Europe Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn
Figure 33. Europe Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn
Figure 34. Europe Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn
Figure 35. Europe Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn
Figure 36. Europe Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn
Figure 37. Europe Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn
Figure 38. Europe Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn
Figure 39. Europe Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn
Figure 40. Breakdown of Europe Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue
Figure 41. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%)
Figure 42. Europe Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn
Figure 43. Europe Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn
Figure 44. Europe Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn
Figure 55. Breakdown of European Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue
Figure 56. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 57. Pharmaceutical CDMO Market in Germany, 2019-2030, $ bn
Figure 58. Pharmaceutical CDMO Market in UK, 2019-2030, $ bn
Figure 59. Pharmaceutical CDMO Market in France, 2019-2030, $ bn
Figure 60. Pharmaceutical CDMO Market in Spain, 2019-2030, $ bn
Figure 61. Pharmaceutical CDMO Market in Italy, 2019-2030, $ bn
Figure 62. Pharmaceutical CDMO Market in Russia, 2019-2030, $ bn
Figure 63. Pharmaceutical CDMO Market in Rest of Europe, 2019-2030, $ bn
Figure 86. Growth Stage of Europe Pharmaceutical CDMO Industry over the Forecast Period
Note: Product cover images may vary from those shown
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
  • Charles River Laboratories
  • CMIC Co. Ltd
  • Covance Inc.
  • Hangzhou Tigermed Consulting Co Ltd
  • ICON Plc
  • IQVIA Holdings Inc.
  • LSK Global Pharma Service Co Ltd
  • Novotech Pty Ltd
  • PAREXEL International Corporation
  • Pharmaceutical Product Development LLC (PPD)
  • PRA Health Sciences Inc.
  • Quanticate Ltd
  • Samsung Bioepis Co. Ltd
  • SGS SA (SGS Life Sciences)
  • Syneos Health Inc.
  • WuXi AppTec Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll